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Abstract 16 
The presence of pharmacologically active compounds (PhACs) in surface waters poses an 17 
environmental risk of chronic exposure to non-target organisms, which is a well-established and 18 
serious concern worldwide. Our aim was to determine the temporal changes in ecological risk quotient 19 
(RQ) based on the concentrations of 42 PhACs from six sampling sites on seven sampling dates in the 20 
water of a freshwater lake in Central Europe preferentially visited by tourists. Our hypothesis was that 21 
the environmental risk increases during the summer holiday season due to the influence of tourists. 22 
Different experimental toxicological threshold concentrations and seasonal measured environmental 23 
concentrations of 16 PhACs were applied to ecological risk assessment. RQs of 4 dominant PhACs 24 
(diclofenac, estrone [E1], estradiol [E2], and caffeine) indicated high ecological risk (RQ > 1) for 25 
freshwater ecosystems. Additionally, our results confirmed the assumptions that the high tourist 26 
season had a significant impact on the calculated RQ, however these results are mainly due to the 27 
concentration and temporal change of particular PhACs, including diclofenac (5.3-419.4 ng/L), E1 28 
(0.1-5.5 ng/L), and E2 (0.1-19.6 ng/L). The seasonal dependent highest RQs changed as follows: 9.80 29 
(June 2017; E2), 1.23 (August 2017; E1), 0.43 (November 2017; E1), 0.51 (April 2018; E1), 5.58 30 
(June 2018, diclofenac), 39.50 (August 2018; diclofenac), and 30.60 (October 2018; diclofenac).  31 
  32 
Keywords 33 
environmental risk assessment, pharmacologically active compounds, ecotoxicological data, seasonal 34 
effects, touristic region, Lake Balaton 35 
 36 
Introduction  37 
Medicine has improved considerably in recent decades, contributing to the increase in the average age 38 
and fast growth of the human population. At the same time, the consumption of medication has 39 
changed significantly (Ginebreda et al. 2010; Guzel et al. 2019), resulted in an increased use of 40 
pharmaceuticals. However, waste water treatment (WWT) technologies are not suitable for removing 41 
all kind of pharmacologically active compounds (PhACs) with the same efficiency, therefore, a large 42 
majority of PhACs with their metabolites and conjugates have been appearing in all environmental 43 
compartments (surface waters, sediment, biota) worldwide (Halling-Sorensen et al. 1998; Kummerer 44 
2004).  45 
This is a concern for several reasons (Daughton and Ternes 1999; Diaz-Cruz et al. 2003). 46 
Information is lacking about possible harmful effects on non-target freshwater organisms (e.g., 47 
zooplankton, molluscs, fish) when different PhACs form a mixture in receiving environments (Guzel 48 
et al. 2019). At the same time, it should also be noted that most measurement and risk assessment have 49 
been based on individual compound but PhACs never occur as single substances in the environment. 50 
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Therefore, to get a realistic picture about ecosystem involvement, investigation and assessment of 51 
multi-component mixture effect of PhACs are required (De Zwart and Posthuma 2005; Lin et al. 2018; 52 
Heys et al. 2016). Additionally, the correct interpretation of measured environmental concentration 53 
(MEC) of PhACs is a big challenge for scientists, even today. Not only is the limited available 54 
experimental toxicity data (median effective concentration [EC50], median lethal concentration 55 
[LC50], and no observed effect concentration [NOEC]) a problem (Ginebreda et al. 2010; Hernando et 56 
al. 2006; la Farre et al. 2008; Thomaidi et al. 2015), but even if such data exist and are accessible, they 57 
are usually described based on different observations (e.g., various endpoints and species) so, in other 58 
words, they are not consistent (Lange and Dietrich 2002). Of course, this is understandable because 59 
different studies of PhACs have been conducted in vivo using different mechanisms, therefore, the 60 
effect of the given PhACs have been observed using different endpoints (e.g., growth, mortality, 61 
reproduction or developmental, behavioural effects, and molecular, cellular, tissue level changes). 62 
Even though the MEC is known, since there is a lack of standardized experimental toxicity data in 63 
many cases (la Farre et al. 2008; Thomaidi et al. 2015), the ecological risk assessment (ERA) cannot 64 
be appropriately performed (Ferrari et al. 2004).  65 
To estimate the harmful effect of PhACs on an ecosystem, a risk quotient (RQ) is usually applied, 66 
which is defined as the ratio of the maximum MEC to the predicted no effect concentrations (PNEC), 67 
where PNEC depends on the available toxicological data (Carlsson et al. 2006; Deo 2014; Ferrari et al. 68 
2004; Hernando et al. 2006; Komori et al. 2013). To get the most realistic ecological RQ values, 69 
PNECs need to be derived from species sensitivity distribution (SSD) curve (Posthuma et al. 2002) or 70 
at least experimental NOEC, or E(L)C50. Other PNECs estimated based on, for example, ECOSAR 71 
(Sanderson et al. 2004) are only used for cases which no laboratory data are available, however, they 72 
need to be managed with a high degree of uncertainty.  73 
In other aspect, the degree of risk depends on the concentration data, the forms and migration of 74 
PhACs in the environmental elements, and these levels are influenced by among other factors, the 75 
efficiency of the WWT technology applied, the resistance of (bio)degradation, complexation, sorption, 76 
bioaccumulation, defined daily doses, dosage of medicine (periodical or continuous), and even 77 
weather conditions (Andreozzi et al. 2002; Bouissou-Schurtz et al. 2014). Furthermore, for a 78 
comprehensive ERA, all environmental elements should be examined because PhACs, depending on 79 
the environmental conditions (e.g., temperature, UV radiation), are distributed between different 80 
matrices (water, sediment, suspended solid, biofilm) (Dobor et al. 2012). Besides environmental 81 
conditions, effect of tourism also needs to be considered for ERA. The improving tourism industry 82 
frequently poses a risk to the ecosystems by the increased load of WWT plant locally and many 83 
recreational activities (e.g., swimming, sailing, kayaking, canoeing, diving, or fishing), respectively 84 
(Hadwen et al. 2005; Katircioglu 2014; Mihalic 2000). Increased PhAC levels, also including 85 
recreational substances (e.g., caffeine and illicit drugs), during high tourism season is a well-known 86 
phenomenon (Guzel et al. 2019; Lin et al. 2018; Nakada et al. 2017; Zhang et al. 2017) in rivers 87 
flowing throughout cities, however, there are only limited data in case of lakes (Maasz et al., 2019). 88 
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Based on all them, the production of an accurate and definite assessment of risk level is a very difficult 89 
and complex task; however, approximate calculations are also necessary and useful to prevent 90 
environmental damage. 91 
This study complements and uses another approach to analyse our earlier screening data resulted 92 
from investigating the presence of 134 PhACs in the surface water of Lake Balaton and its catchment 93 
area from June 2017 to April 2018. Taking the studied period and sampled sites belonging to the lake 94 
into account, 39 PhACs were detected and quantified in water samples from the lake (Maasz et al. 95 
2019). This was the first extended qualitative and quantitative study to present data on the occurrence 96 
of PhACs derived from several chemical classes in this lake. Measurements have continued and the 97 
database has been complemented with further MEC data from June, August, and October 2018. In 98 
total it was possible to consider the ERAs of 42 PhACs. The main goals of the present study were to 99 
estimate the environmental risk of single and mixed PhACs in the surface water of Lake Balaton, a 100 
popular touristic region in Europe, subsequently, to explore a possible correlation between the 101 
magnitude of the actual hazard and impacts of seasonal changes (spring, summer, autumn, winter).  102 
 103 
Experimental methodology  104 
Study area  105 
The study was conducted in Lake Balaton (Fig. 1), which is one of the largest (A: 594 km2, mean 106 
depth: 3.2 m, V: ~1.8 km3) freshwater shallow lakes in Central Europe (Hungary) (Istvanovics et al. 107 
2007) and very popular with tourists. The Lake Balaton resort area is an internationally important 108 
tourist and recreation centre visited by millions of tourists a year, especially in summer season (Maasz 109 
et al. 2019; URL1). The maximum number of guest nights at commercial accommodation in the 110 
counties surrounding Lake Balaton approaches ~900,000 in an average summer month (e.g., August) 111 
in a high tourist season also in 2017 and 2018, while this value is only ~300,000 in winter (see 112 
Supplementary Fig. 1). The human population shows unequal spatio-temporal distribution in this 113 
region; two-thirds of the local resident population (~380,000 people) inhabit the near-coastal area of 114 
the lake (URL1; URL2). Nowadays, more than 40 WWT plants are being situated in the catchment 115 
area of Lake Balaton, the largest one (with a capacity of 50,000 m3/day) can be found in Zalaegerszeg 116 
(URL3) which is the largest town of the catchment area (with ~60,000 inhabitants) (URL1). This town 117 
is located on the riverbank of River Zala (the largest tributary of Lake Balaton) supplying ~50% of the 118 
lake's total surface water input (URL3). Since the waste water effluent reaches directly the River Zala 119 
it also plays a potential role in the PhACs pollution of Lake Balaton. 120 
 121 
Sample collection, preparation, and measurement  122 
Designation of sampling sites (Fig. 1) was based on our previous study (Maasz et al. 2019) and the 123 
current research may be considered to be the continuation of that work. Forty-two water samples used 124 
for the present study were collected in June, August, and November of 2017, and April, June, August, 125 
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and October of 2018 from six sampling sites on the littoral region of the lake (see Supplementary 126 
Table 1). 127 
All water samples were collected by a water-column sample device from the middle of the water 128 
level in 2 L amber silanized glass bottles with Teflon-faced caps. One litre of each sample was 129 
acidified by applying 100% formic acid (due to sorbent type compatibility) to pH 3.5–4.0. Internal 130 
standards (Citalopram-d6, Carbamazepine-d10, E2-13C3, and N-ethyloxazepam) were added to 131 
samples before filtration; the final concentration was 5 ng/L for each standard and these were used for 132 
the quantification of samples. After spiking by internal standards, samples were vacuum filtered 133 
through a GF/F 0.7 μm glass microfibre filter (#516-0345, VWR). The Solid Phase Extraction (SPE) 134 
of samples was implemented using AutoTrace 280 automated SPE system (Thermo Scientific). SPE 135 
extracts were evaporated using an inert nitrogen gas stream. Analytical measurements and detection 136 
were performed using an ACQUITY UPC2 Supercritical Fluid Chromatography System (Waters) 137 
coupled with a Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters). Data were recorded by 138 
MassLynx software (V4.1 SCN950) and evaluated by TargetLynx XS software. The details of 139 
analytical measurements with validation parameters of measured PhACs and data evaluation is 140 
published in our previous paper (Maasz et al. 2019).  141 
Calculation of ERA 142 
ERA is based on ecotoxicological threshold data from experiments on aquatic organisms (algae, 143 
Cladocera [usually Daphnia sp.], and/or fish species). Accordingly, E(L)C50 and NOEC values 144 
derived from acute and chronic tests, respectively, are taken into consideration. Applying them, the 145 
SSD curve and the hazard concentrations (e.g., HC5, which 5% of the species in the SSD exhibit an 146 
effect; Supplementary Fig. 2) are also determined by Chemical Aquatic Fate and Effects (CAFE) 147 
database and software (Bejarano et al. 2016). Using these data, the PNEC is calculated (Eq. 1) as the 148 
ratio of the E(L)C50, NOEC or HC5 data and an Assessment Factor (AF); 149 
 150 
 𝑃𝑁𝐸𝐶 =
 E(L)C50 or NOEC or HC5
AF
 (1)  
 151 
The magnitude of the AF depends on the available toxicological information. The reliability of the 152 
results increases if toxicological data for aquatic organisms are available at multiple different trophic 153 
levels. Hence, the value of AF is decreased in cases of large and relevant datasets. For example, if 154 
toxicity data are only available based on E(L)C50 an AF of 1000 is used, but where NOEC is derived 155 
from experiments with a single trophic level (e.g., fish), an AF of 100 is applied and if NOEC for two 156 
trophic levels are available (e.g., fish and Cladocera), AF = 50 is used. If NOECs are known for all 157 
three trophic levels then AF is equal to 10 (Hamre 2006). In case of using at least five different species 158 
(independently on trophic levels) with the same toxicological data, meaning the HC5 value is known, 159 
AF = 5 (Amiard and Amiard-Triquet, 2015).    160 
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If different toxicity data are available for each trophic level, the lowest concentration limit results 161 
will be used to determine PNEC, as ERA is based on the most sensitive elements of the ecosystem, in 162 
order to estimate ecological hazard for the worst-case scenario (Thomaidi et al. 2015). 163 
If no experimental toxicological data are available then predicted E(L)C50 values from the US 164 
Environmental Protection Agency Ecological Structure Activity Relationships Class Program 165 
(ECOSAR database) are usually used (Sanderson et al. 2004) however, the data from this database are 166 
highly uncertain, therefore, the applicable AF = 1000 (Zhang et al. 2017).   167 
ERA characterization is possible after measurement of environmental concentrations and 168 
determination of the toxicology threshold values of investigated pollutants, because RQ, which is used 169 
to categorize harmful effects for the ecosystem, is defined as the ratio of the maximum MEC to the 170 
PNEC (Eq. 2); 171 
 172 
 𝑅𝑄 =
MEC
PNEC
 (2) 
 173 
In general, RQ < 0.01 denotes a negligible risk, RQ < 0.1 reveals a low risk, 0.1 < RQ < 1 represents a 174 
medium risk, and RQ > 1 indicates a high ecological risk to aquatic organisms (Ma et al. 2016; EU 175 
Commission 2003).  176 
The following method was used to track risk levels over time. From the six sampling sites (Fig. 1), 177 
the highest MEC was selected for each PhAC and investigated month. Their maximum RQ values 178 
among six sampled sites were defined as the maxRQ. From the highest maxRQ in each sampled 179 
month was determined, termed maxRQperiod; this is independent of the kind of PhAC and its 180 
relationship over time can be studied. When the highest maxRQs were calculated for the whole studied 181 
period, separately for each PhAC, we generally define this value as MAX RQ values. Based on MAX 182 
RQs, the different level of risk (high, medium, low, and negligible) for each PhACs can be determined 183 
in the whole investigation period (see Supplementary Table 2). 184 
In the vast majority of aquatic mixture toxicity studies, the toxicity of a mixture is assessed 185 
by Concentration Addition (CA) model, neglected the toxic modes of action of the mixture 186 
constituents. The CA model implies that the contribution of the individual toxicants to the 187 
overall effect can be added in the form of Toxic Units (TU). The CA of a mixture can be 188 
described by the following equation (De Zwart and Posthuma 2005) with slight modifications: 189 
 190 
 𝑇𝑈 = ∑
𝑀𝐸𝐶𝑖
𝐸(𝐿)𝐶50𝑖 𝑜𝑟 𝑁𝑂𝐸𝐶𝑖
𝑛
𝑖=1
 (3) 
 191 
 where MECi, is the actual concentrations and E(L)C50i or NOECi is the exposure 192 
concentrations of a given PhAC that cause the same standard toxicological response for all 193 
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compounds. The TU is a dimensionless expression. It has only one threshold; if its value is 194 
greater than 1, it implies a potential risk. 195 
 196 
Results and discussion  197 
Seasonal changes in PhACs concentration and ERA 198 
New PhACs, theophylline (28.9-59.6 ng/L), barbital (94.8 ng/L) and diclofenac (5.3-419.4 ng/L) (see 199 
detailed in Supplementary Table 1) were detected in the lake in addition to the 39 compounds 200 
published earlier (Maasz et al. 2019). The collection of the necessary raw predicted and/or 201 
experimental toxicological data (E(L)C50, NOEC, and HC5) and the determination of AF and PNEC 202 
values of 42 PhACs, summarized in Table 1, were essential to perform ERA. Table 1 contains various 203 
PNEC values in case of some PhACs. For example, 6 different PNECs were calculable in range of 0.1-204 
44.0 in the case of E2 from available ecotoxicological data. However, if the data collection is not 205 
sufficiently thorough and the selection method among them is not appropriate (e.g., ECOSAR is 206 
applied instead of available laboratory data, or acute experimental results are used in place of known 207 
chronic outcomes), the ERA will also be wrong even in orders of magnitude. Since the experimental 208 
toxicological data and realistic PNEC values were found only in case of 16 PhACs from 42, ERA and 209 
seasonal fluctuation of RQs were emphasized to these compounds in this study. Table 2 shows the 210 
results of the ERA (based on RQ values) calculated from MEC, and the PNEC data. The highest RQ 211 
values in the months investigated (maxRQperiod) were as follows: 9.80 (June 2017; E2), 1.23 (August 212 
2017; E1), 0.43 (November 2017; E1), 0.51 (April 2018; E1), 5.58 (June 2018, diclofenac), 39.50 213 
(August 2018; diclofenac), and 30.60 (October 2018; diclofenac). Therefore, based on these results, 214 
we concluded that the values of maxRQperiod varied seasonally. The seasonal fluctuation of 215 
maxRQperiod was plotted and displayed in Fig. 2, this is the first study to present such investigation in 216 
freshwater lakes. This fluctuation in our study area was caused by changes in the presence and 217 
concentration of E1, E2, and diclofenac especially. The risk of these PhACs presented was typically 218 
higher during the summer seasons (e.g., caffeine: 1.16, E2: 9.80, and E1: 5.52 in June or August) than 219 
in any other months investigated (e.g., caffeine: 0.00 [<LOQ], E2: 0.00 [<LOQ], and E1: 0.43 in 220 
November). Similar season-influenced phenomena in detected environmental concentration values of 221 
recreational substances (e.g., illicit drugs) have already been observed in Lake Balaton by our research 222 
group (Maasz et al. 2019) and the occurrence and concentration of other PhACs (e.g., 223 
methamphemtamine, amphetamine, ketamine, and ephedrine) have been also reported in the urban 224 
rivers of Beijing in China (Zhang et al. 2017). The frequency of occurrence and levels of several 225 
PhACs (e.g., carbamazepine, caffeine, citalopram, and diclofenac) have also been found to differ by 226 
season in River Ceyhan in Turkey (Guzel et al. 2019) and Xiangjiang River in China (Lin et al. 2018). 227 
Regarding the contamination input aspect of surface water, the environmental concentrations of 228 
PhACs vary depending on their chemical stability, biodegradability, physicochemical characteristics, 229 
and the efficiency of WWT technology (Bouissou-Schurtz et al. 2014). For example, microbiological 230 
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activity is influenced by temperature during WWT, as the efficiency of bacterial removal decreases in 231 
winter (Couto et al. 2019). Climate effects (e.g., temperature, ultraviolet exposure, rainfall, wind) can 232 
also modify the measured concentration of PhACs at the investigated sites (Zhang et al. 2017). 233 
Moreover, change of season affects tourists, thereby the spatial distribution of the population, and, as 234 
consumption and excretion of PhACs contribute to the detected contamination, the impact of tourism 235 
cannot be neglected. Additionally, the typical health problems and most-consumed PhACs change 236 
depending on weather conditions and season. For some PhACs, seasonal consumption patterns were 237 
also observed; for example, some antipyretics (e.g., diclofenac, ibuprofen, and naproxen) have higher 238 
usage rates during winter than spring, summer or autumn. At the same time, similar to our 239 
observations in this study, other PhACs such as carbamazepine showed a similar presence in all 240 
seasonal periods (Camacho-Munoz et al. 2014; Couto et al. 2019). Consequently, the season-241 
influenced phenomenon of PhACs is the outcome of a very difficult, complex, and multi-factor 242 
process.  243 
As Table 2 indicates, based on our MAX RQ data, 4 PhACs in Lake Balaton were > 1 including 244 
diclofenac (39.50), E2 (9.80), E1 (5.52), and caffeine (1.16), indicating high ecological risk for 245 
freshwater ecosystems. Another 3 PhACs received a medium (EE2 [0.41], E3 [0.28], citalopram 246 
[0.24]) classification and the remaining 9 were negligible. A study collecting the PhACs 247 
concentrations in European surface waters and performing ERA have already reported high risk levels 248 
in case of all 7 compounds, although the standard method of calculating ERA based on maximal 249 
MECs results in overestimation of the actual risk levels. To avoid overestimation, updated RQs can be 250 
assessed considering the frequency that MECs exceed PNECs, and using mean MECs instead of 251 
maximal MECs (Zhou et al. 2019). Our data were also investigated using this improved method; the 252 
updated ERA results showed that risk of PhACs decreases at least one level compared with MAX RQs 253 
(data not shown), however, seasonal effects can be better observed considering the maxRQperiod 254 
values presented in this paper. 255 
Mixture effect of the examined 16 PhACs was estimated based on their NOEC levels. The 256 
characteristic shape of the TU (De Zwart and Posthuma 2005) curve reflects the seasonal variations of 257 
mixture effect, as well. Figure 3 shows that the TU and number of guest nights change together 258 
depending on time, their maximum values (TU: 22.75, and guest night: ~871,000 in August) are in 259 
high tourist seasons while their minimum ones (TU: 0.01, and guest night: ~309,000 in November) are 260 
out of season. Although with only a difference of one order of magnitude, but the fluctuation of 261 
mixture RQ shows similar seasonal changes in Xiangjiang River (Lin et al. 2018) like TU observing in 262 
our study area. Since the data used to calculate the mixture RQs are derived from RQs, they can be 263 
categorized as the same risk criteria. However, as already mentioned, TU has only one threshold. If its 264 
value greater than 1, it indicates a possible risk. 265 
This is the first ERA based on changes in maxRQperiod values from a specific case study in Lake 266 
Balaton, which makes an effort to prove the harmful effect of summer tourist months on a freshwater 267 
lake.  268 
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 269 
Summary 270 
Season-dependent fluctuation of magnitude of risk is apparent (maxRQperiod, Fig. 2.), therefore our 271 
hypothesis that the environmental risk increases during the holiday season in the study area, Lake 272 
Balaton, is proven. However, it must be noted that only 16 PhACs from the 42 presenting magnitude of 273 
the risk because they have available experimental ecotoxicological data (NOEC) applied to ERA. 274 
According to our results when considering all MAX RQs presented, the PhACs with at least medium 275 
risk level were caffeine, citalopram, diclofenac, E1, E2, E3, and EE2 in the study area during the period 276 
investigated. More attention should be paid to these 7 PhACs in the future in order to diagnose and 277 
predict their effects on aquatic ecosystems. The TU curve (Fig. 3.) reflects the seasonal variations of 278 
mixture effect which correlate well with the change of maxRQperiods and the number of guest nights.  279 
 280 
Conclusions  281 
The fluctuation of summed MEC, maxRQperiod, and TU suggested the possibility of harmful effects 282 
on aquatic ecosystems in the summer tourist season. Caffeine, citalopram, diclofenac, E1, E2, E3, and 283 
EE2 presented at least a medium risk at least once during the whole period of investigation in Lake 284 
Balaton, the largest shallow lake in Central Europe, based on MAX RQ results.   285 
There is a real need for ongoing water quality monitoring and repeated toxicological testing for PhACs 286 
to ensure the real risk levels are understood. Besides, during our work we found several discrepancy in 287 
raw ecotoxicological data, therefore, we propose to develop a unified PNEC database, including data 288 
regarding habitats, endpoints, and compounds, ensuring reliable and comparable results for ERA. 289 
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 294 
Figure legends 295 
Fig. 1 - Hydrogeography of Lake Balaton. The positions marked from 1 to 6 belong to the near-coastal 296 
area of the lake. The sampling points (by coordinates) are as follows: 1 - Szigliget (46.78541, 297 
17.4349), 2 - Révfülöp (46.82411, 17.60672), 3 - Balatonlelle (46.79708, 17.72528), 4 - Tihany-298 
Sajkod (46.90339, 17.85037), 5 - Zamárdi (46.88525, 17.93139), and 6 - Siófok (46.91102, 18.04604) 299 
 300 
Fig. 2 - Seasonal fluctuation of maxRQperiods in Lake Balaton in the investigated months.  301 
(striped – summer seasons; dashed vertical – autumn seasons; gridded – winter season; waved – spring 302 
season) E1 – estrone; E2- estradiol 303 
 304 
Fig. 3 - Seasonal fluctuation of TU and number of guest nights in Lake Balaton in the investigated 305 
months.  306 
 307 
Table 1 - Raw toxicological data for the 42 investigated PhACs. Ecotoxicological data are collected 308 
from ECOSAR (Sanderson et al., 2004), and/or CAFE database and/or several papers (see references), 309 
with their AF and calculated PNECs in ng/L (n.d. = no data) 310 
Table 2 - MEC data (in ng/L), calculated maxRQ, maxRQperiod, and MAX RQ values of PhACs, as 311 
well as risk levels of Lake Balaton in the seven investigated periods (LOQ = limit of quantitation) 312 
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PhACs 
Ecotoxicologycal data 
AF 
PNEC 
 Ref. 
Based on acute test results Based on chronic test result 
Based 
on SSD  
E(L)C50(algae) E(L)C50(Cladocera) E(L)C50(fish) NOEC(algae) NOEC(Cladocera) NOEC(fish) HC5 
[ng/L] [ng/L] 
alprazolam 6.28E+05 5.08E+05 5.41E+06 n.d. n.d. n.d. n.d. 1.00E+03 5.08E+02 Sanderson et al. 2004 
atropine 2.66E+06 6.64E+06 2.00E+07 n.d. n.d. n.d. n.d. 1.00E+03 2.66E+03 Sanderson et al. 2004 
barbital n.d. n.d. 1.16E+09 n.d. n.d. n.d. n.d. 1.00E+03 1.16E+06 Sanderson et al. 2004 
benzoylecgonine 1.20E+10 6.81E+09 3.35E+10 n.d. n.d. n.d. n.d. 1.00E+03 6.81E+06 Mendoza et al. 2014 
bisoprolol 3.15E+06 8.20E+06 1.13E+08 n.d. n.d. n.d. n.d. 1.00E+03 3.15E+03 Sanderson et al. 2004 
bupropion 3.30E+06 9.50E+05 3.30E+07 n.d. n.d. n.d. n.d. 1.00E+03 9.50E+02 Vestel et al. 2016 
buspirone 2.60E+06 5.16E+06 6.70E+07 n.d. n.d. n.d. n.d. 1.00E+03 2.60E+03 Sanderson et al. 2004 
caffeine 
6.85E+06 4.70E+07 8.05E+08 n.d. n.d. n.d. n.d. 1.00E+03 6.85E+03 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. 1.20E+02 n.d. n.d. 1.00E+02 1.20E+00 Lu et al. 2013 
n.d. n.d. n.d. n.d. n.d. n.d. 1.16E+04 5.00E+00 2.32E+03 CAFE 
carbamazepine 
8.15E+06 6.36E+06 1.40E+07 n.d. n.d. n.d. n.d. 1.00E+03 6.36E+03 Sanderson et al. 2004 
n.d. n.d. n.d. 1.00E+06 n.d. n.d. n.d. 
1.00E+01 1.00E+04 
Zhang et al. 2012 
n.d. n.d. n.d. n.d. 1.00E+05 n.d. n.d. Lürling et al. 2006 
n.d. n.d. n.d. n.d. n.d. 1.78E+06 n.d. Madureira et al. 2011 
citalopram 
7.29E+05 6.35E+05 6.88E+06 n.d. n.d. n.d. n.d. 1.00E+03 6.35E+02 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. 1.00E+03 n.d. 1.00E+02 1.00E+01 Olsén et al. 2014 
clozapine 
1.47E+06 2.15E+06 2.60E+07 n.d. n.d. n.d. n.d. 1.00E+03 1.47E+03 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. 2.85E+04 n.d. 1.00E+02 2.85E+02 Nallani, 2010 
cocaine 2.28E+06 4.91E+06 1.30E+07 n.d. n.d. n.d. n.d. 1.00E+03 2.28E+03 Sanderson et al. 2004 
diazepam 
1.42E+06 2.26E+06 2.80E+07 n.d. n.d. n.d. n.d. 1.00E+03 1.42E+03 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. 2.60E+05 n.d. 1.00E+02 2.60E+03 Oggier et al. 2010 
diclofenac 
7.71E+06 4.24E+06 4.94E+06 n.d. n.d. n.d. n.d. 1.00E+03 4.24E+03 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5.00E+01 EU JRC, 2018 
n.d. n.d. n.d. n.d. n.d. 1.06E+03 n.d. 1.00E+02 1.06E+01 Schwaiger et al. 2004 
E1 
1.66E+06 5.60E+05 7.40E+04 n.d. n.d. n.d. n.d. 1.00E+03 7.40E+01 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 3.60E+00 EU JRC, 2018 
n.d. n.d. n.d. n.d. n.d. 1.00E+02 n.d. 1.00E+02 1.00E+00 Dammann et al. 2011 
E2 
8.00E+05 2.77E+05 4.40E+04 n.d. n.d. n.d. n.d. 1.00E+03 4.40E+01 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 4.00E-01 EU JRC, 2018 
n.d. n.d. n.d. 8.00E+04 n.d. n.d. n.d. 
1.00E+01 1.00E-01 
Julius et al. 2007 
n.d. n.d. n.d. n.d. 1.00E+02 n.d. n.d. Marcial et al. 2003 
n.d. n.d. n.d. n.d. n.d. 1.00E+00 n.d. 
Routledge et al. 1998; 
Lahnsteiner et al. 2006 
n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7.30E-01 Wu et al. 2014  
19 
 
n.d. n.d. n.d. n.d. n.d. n.d. 1.00E+01 5.00E+00 2.00E+00 CAFE 
E3 
4.39E+06 1.45E+06 1.50E+04 n.d. n.d. n.d. n.d. 1.00E+03 1.50E+01 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. 4.65E+01 n.d. 1.00E+02 4.65E-01 Lei et al. 2014 
EE2 
6.77E+05 2.34E+05 4.00E+04 n.d. n.d. n.d. n.d. 1.00E+03 4.00E+01 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. 4.40E+01 n.d. 1.00E+02 4.40E-01 Kristensen et al. 2005 
fluoxetine 
3.45E+05 1.78E+05 1.72E+06 n.d. n.d. n.d. n.d. 1.00E+03 1.78E+02 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. n.d. 5.40E+04 n.d. 
5.00E+01 1.08E+03 
Menningen et al. 2010 
n.d. n.d. n.d. 7.20E+04 n.d. n.d. n.d. DeLorenzo and Fleming 2008  
ketamin 8.61E+05 1.07E+06 1.30E+07 n.d. n.d. n.d. n.d. 1.00E+03 8.61E+02 Sanderson et al. 2004 
lamotrigine n.d. n.d. n.d. n.d. n.d. 1.50E+10 n.d. 1.00E+02 1.50E+08 Deo 2014 
levonorgestrel 2.28E+06 1.31E+06 5.56E+05 n.d. n.d. n.d. n.d. 1.00E+03 5.56E+02 Sanderson et al. 2004 
lidocaine 2.61E+06 7.52E+06 1.07E+08 n.d. n.d. n.d. n.d. 1.00E+03 2.61E+03 Sanderson et al. 2004 
losartan n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 1.90E+03 Helwig et al. 2016 
MDMA  2.30E+06 2.16E+05 2.42E+07 n.d. n.d. n.d. n.d. 1.00E+03 2.16E+02 Mendoza et al. 2014 
methadone 4.12E+07 3.81E+07 1.10E+08 n.d. n.d. n.d. n.d. 1.00E+03 3.81E+04 Sanderson et al. 2004 
metoprolol n.d. n.d. n.d. n.d. 6.15E+06 n.d. n.d. 1.00E+02 6.15E+04  Dzialowski et al. 2006 
midazolam 4.65E+05 2.89E+05 2.90E+06 n.d. n.d. n.d. n.d. 1.00E+03 2.89E+02 Sanderson et al. 2004 
mirtazapine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 3.20E+04 Helwig et al. 2016 
naproxen 2.30E+07 1.51E+07 2.43E+07 n.d. n.d. n.d. n.d. 1.00E+03 1.51E+04 Sanderson et al. 2004 
nordiazepam 1.19E+06 1.71E+06 2.10E+07 n.d. n.d. n.d. n.d. 1.00E+03 1.19E+03 Sanderson et al. 2004 
olanzapine 1.41E+08 n.d. n.d. n.d. n.d. n.d. n.d. 1.00E+03 1.41E+05 Jiahua 2015 
perindopril n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 9.90E+05 Webb 2001 
progesterone 
3.30E+06 1.00E+06 7.33E+05 n.d. n.d. n.d. n.d. 1.00E+03 7.33E+02 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. 1.00E+05 n.d. n.d. 1.00E+02 1.00E+03 Kashian et al. 2004 
quetiapine n.d. n.d. n.d. n.d. n.d. 1.00E+05 n.d. 1.00E+01 1.00E+04 AstraZeneca 
testosterone 
2.90E+06 1.70E+06 1.43E+06 n.d. n.d. n.d. n.d. 1.00E+03 1.43E+03 Sanderson et al. 2004 
n.d. n.d. n.d. n.d. 1.00E+05 n.d. n.d. 1.00E+02 1.00E+03 Clubbs and Brooks, 2007 
tetracaine 7.45E+05 1.36E+06 2.20E+06 n.d. n.d. n.d. n.d. 1.00E+03 7.45E+02 Sanderson et al. 2004 
theophylline 9.70E+06 1.00E+06 1.68E+09 n.d. n.d. n.d. n.d. 1.00E+03 1.00E+03 Sanderson et al. 2004 
tiapride 8.72E+06 4.80E+07 7.89E+08 n.d. n.d. n.d. n.d. 1.00E+03 8.72E+03 Sanderson et al. 2004 
tramadol 1.04E+06 3.20E+04 7.72E+06 n.d. n.d. n.d. n.d. 1.00E+03 3.20E+01 Sanderson et al. 2004 
verapamil n.d. n.d. 3.60E+07 n.d. n.d. n.d. n.d. 1.00E+03 3.60E+04 Sanderson et al. 2004 
zolpidem 6.35E+05 5.19E+05 5.54E+06 n.d. n.d. n.d. n.d. 1.00E+03 5.19E+02 Sanderson et al. 2004 
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PhACs 
Lake Balaton (1-6) 
June 2017 August 2017 November 2017 April 2018 June 2018 August 2018 October 2018 
June 2017 - October 
2018 
MEC  
maxRQ  
MEC  
maxRQ 
MEC  
maxRQ  
MEC] 
maxRQ 
MEC  
maxRQ 
MEC  
maxRQ 
MEC  
maxRQ MAX RQ 
Level of 
risk [ng/L] [ng/L] [ng/L] [ng/L] [ng/L] [ng/L] [ng/L] 
diclofenac <LOQ - <LOQ - <LOQ - <LOQ - 5.91E+01 5.58E+00 4.19E+02 3.95E+01 3.24E+02 3.06E+01 3.95E+01 high 
E2 1.96E+01 9.80E+00 2.00E-01 1.00E-01 <LOQ - 1.95E-01 9.75E-02 3.00E+00 1.50E+00 <LOQ - 6.50E-02 3.25E-02 9.80E+00 high 
E1 5.52E+00 5.52E+00 1.23E+00 1.23E+00 4.30E-01 4.30E-01 5.10E-01 5.10E-01 <LOQ - 1.81E+00 1.81E+00 4.25E-01 4.25E-01 5.52E+00 high 
caffeine <LOQ - 8.99E+01 3.88E-02 <LOQ - <LOQ - 1.39E+03 6.00E-01 2.68E+03 1.16E+00 2.42E+03 1.04E+00 1.16E+00 high 
EE2 <LOQ - <LOQ - 1.80E-01 4.09E-01 <LOQ - <LOQ - <LOQ - <LOQ - 4.09E-01 medium 
E3 1.00E-01 2.15E-01 1.30E-01 2.80E-01 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 2.80E-01 medium 
citalopram 1.30E-01 1.30E-02 2.00E-01 2.00E-02 <LOQ - 2.44E+00 2.44E-01 <LOQ - <LOQ - <LOQ - 2.44E-01 medium 
carbamazepine 6.88E+01 6.88E-03 4.63E+01 4.63E-03 1.59E+01 1.59E-03 7.75E+01 7.75E-03 1.45E+01 1.45E-03 1.66E+01 1.66E-03 2.41E+01 2.41E-03 7.75E-03 negligible 
clozapine 5.40E-01 1.89E-03 5.50E-01 1.93E-03 <LOQ - <LOQ - <LOQ - <LOQ - 5.54E-01 1.94E-03 1.94E-03 negligible 
fluoxetine 1.68E+00 1.56E-03 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 1.56E-03 negligible 
progesterone 9.60E-01 9.60E-04 1.31E+00 1.31E-03 <LOQ - 1.13E+00 1.13E-03 <LOQ - <LOQ - <LOQ - 1.31E-03 negligible 
testosterone <LOQ - <LOQ - <LOQ - 1.09E+00 1.09E-03 <LOQ - <LOQ - <LOQ - 1.09E-03 negligible 
diazepam <LOQ - <LOQ - <LOQ - 2.50E-01 9.62E-05 <LOQ - <LOQ - <LOQ - 9.62E-05 negligible 
metoprolol <LOQ - 5.08E+00 8.26E-05 <LOQ - 1.17E+00 1.90E-05 2.64E-01 4.28E-06 <LOQ - 1.25E+00 2.04E-05 8.26E-05 negligible 
quetiapine 1.20E-01 1.20E-05 1.10E-01 1.10E-05 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 1.20E-05 negligible 
lamotrigine 8.57E+00 5.71E-08 1.62E+02 1.08E-06 2.21E+01 1.47E-07 3.34E+01 2.23E-07 <LOQ - <LOQ - 5.54E+01 3.69E-07 1.08E-06 negligible 
maxRQperiod 9.80E+00 1.23E+00 4.30E-01 5.10E-01 5.58E+00 3.95E+01 3.06E+01   
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Supplementary Table 1  - Concentration levels of 42 detected PhCAs in 6 sites of Lake Balaton in 7 investigated periods with their limit of quantification 
(LOQ), minimum (MIN), maximum (MAX) and frequency of occurrence (FO) data, - represents <LOQ 
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Supplementary Fig. 1 - Seasonal fluctuation of summed MEC (sumMEC) and number of guest nights in Lake Balaton in the investigated 
months  
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PhACs 
Lake Balaton (1-6) 
June 2017 August 2017 November 2017 April 2018 June 2018 August 2018 October 2018 June 2017 - October 2018 
MEC  
maxRQ  
MEC  
maxRQ 
MEC  
maxRQ  
MEC] 
maxRQ 
MEC  
maxRQ 
MEC  
maxRQ 
MEC  
maxRQ MAX RQ Level of risk 
[ng/L] [ng/L] [ng/L] [ng/L] [ng/L] [ng/L] [ng/L] 
E2 1.96E+01 
4.45E-01 
2.00E-01 
4.55E-03 
<LOQ - 1.95E-01 
4.43E-03 
3.00E+00 
6.81E-02 
<LOQ - 6.50E-02 
1.48E-03 4.45E-01 medium 
4.90E+01 5.00E-01 4.88E-01 7.50E+00 1.63E-01 4.90E+01 high 
1.96E+02 2.00E+00 1.95E+00 3.00E+01 6.50E-01 1.96E+02 high 
2.68E+01 2.74E-01 2.67E-01 4.11E+00 8.90E-02 2.68E+01 high 
1.96E+01 2.00E-01 1.95E-01 3.00E+00 6.50E-02 1.96E+01 high 
9.80E+00 1.00E-01 9.75E-02 1.50E+00 3.25E-02 9.80E+00 high 
caffeine <LOQ - 8.99E+01 
1.31E-02 
<LOQ - <LOQ - 1.39E+03 
2.03E-01 
2.68E+03 
3.90E-01 
2.42E+03 
3.53E-01 3.90E-01 medium 
3.88E-02 6.00E-01 1.16E+00 1.04E+00 1.16E+00 high 
tramadol 4.90E-01 1.53E-02 6.10E+00 1.91E-01 1.54E+00 4.81E-02 3.02E+00 9.44E-02 9.02E-01 2.82E-02 8.34E-01 2.60E-02 7.94E-01 2.48E-02 1.91E-01 medium 
diclofenac <LOQ - <LOQ - <LOQ - <LOQ - 5.91E+01 
1.40E-02 
4.19E+02 
9.89E-02 
3.24E+02 
7.65E-02 9.89E-02 low 
1.18E+00 8.38E+00 6.48E+00 8.38E+00 high 
5.58E+00 3.95E+01 3.06E+01 3.95E+01 high 
E1 5.52E+00 
7.46E-02 
1.23E+00 
1.66E-02 
4.30E-01 
5.81E-03 
5.10E-01 
6.89E-03 
<LOQ - 1.81E+00 
2.44E-02 
4.25E-01 
5.74E-03 7.46E-02 low 
1.53E+00 3.42E-01 1.19E-01 1.42E-01 5.03E-01 1.18E-01 1.53E+00 high 
5.52E+00 1.23E+00 4.30E-01 5.10E-01 1.81E+00 4.25E-01 5.52E+00 high 
theophylline <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 5.96E+01 5.96E-02 5.96E-02 low 
MDMA <LOQ - 9.15E+00 4.24E-02 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 4.24E-02 low 
lidocaine 4.22E+01 1.62E-02 3.55E+00 1.36E-03 1.82E+00 6.98E-04 5.81E+00 2.22E-03 1.09E+01 4.16E-03 2.42E+00 9.27E-04 1.50E+00 5.75E-04 1.62E-02 low 
carbamazepine 6.88E+01 
1.08E-02 
4.63E+01 
7.28E-03 
1.59E+01 
2.50E-03 
7.75E+01 
1.22E-02 
1.45E+01 
2.28E-03 
1.66E+01 
2.61E-03 
2.41E+01 
3.79E-03 1.22E-02 low 
6.88E-03 4.63E-03 1.59E-03 7.75E-03 1.45E-03 1.66E-03 2.41E-03 7.75E-03 negligible 
ketamin <LOQ - 8.79E+00 1.02E-02 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 1.02E-02 low 
fluoxetine 1.68E+00 
9.44E-03 
<LOQ - <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 
9.44E-03 negligible 
1.56E-03 1.56E-03 negligible 
E3 1.00E-01 
6.67E-03 
1.30E-01 
8.67E-03 
<LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 
8.67E-03 negligible 
2.15E-01 2.80E-01 2.80E-01 medium 
bupropion <LOQ - <LOQ - <LOQ - 6.59E+00 6.94E-03 <LOQ - <LOQ - <LOQ - 6.94E-03 negligible 
midazolam <LOQ - <LOQ - <LOQ - 1.74E+00 6.00E-03 <LOQ - <LOQ - <LOQ - 6.00E-03 negligible 
bisoprolol 6.28E+00 1.99E-03 1.67E+01 5.29E-03 3.35E+00 1.06E-03 5.35E-01 1.70E-04 1.98E+00 6.26E-04 2.50E+00 7.92E-04 2.70E+00 8.56E-04 5.29E-03 negligible 
EE2 <LOQ - <LOQ - 1.80E-01 
4.50E-03 
<LOQ - <LOQ - <LOQ - <LOQ - 
4.50E-03 negligible 
4.09E-01 4.09E-01 medium 
levonorgestrel <LOQ - <LOQ - <LOQ - 1.84E+00 3.31E-03 <LOQ - <LOQ - 2.31E+00 4.16E-03 4.16E-03 negligible 
citalopram 1.30E-01 
2.05E-04 
2.00E-01 
3.15E-04 
<LOQ - 2.44E+00 
3.83E-03 
<LOQ - <LOQ - <LOQ - 
3.83E-03 negligible 
1.30E-02 2.00E-02 2.44E-01 2.44E-01 medium 
buspirone <LOQ - 1.20E-01 4.61E-05 <LOQ - 5.94E+00 2.28E-03 <LOQ - <LOQ - <LOQ - 2.28E-03 negligible 
27 
 
naproxen <LOQ - 2.19E+00 1.45E-04 <LOQ - <LOQ - <LOQ - <LOQ - 2.77E+01 1.83E-03 1.83E-03 negligible 
progesterone 9.60E-01 
1.31E-03 
1.31E+00 
1.79E-03 
<LOQ - 1.13E+00 
1.54E-03 
<LOQ - <LOQ - <LOQ - 
1.79E-03 negligible 
9.60E-04 1.31E-03 1.13E-03 1.31E-03 negligible 
alprazolam 1.40E-01 2.76E-04 8.80E-01 1.73E-03 3.30E-01 6.50E-04 7.05E-01 1.39E-03 <LOQ - <LOQ - 4.52E-01 8.89E-04 1.73E-03 negligible 
tiapride 2.53E+00 2.90E-04 1.44E+01 1.66E-03 1.18E+01 1.36E-03 1.20E+01 1.38E-03 5.94E-01 6.81E-05 1.25E+00 1.44E-04 1.33E+00 1.53E-04 1.66E-03 negligible 
tetracaine 1.18E+00 1.58E-03 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 1.58E-03 negligible 
nordiazepam 1.39E+00 1.17E-03 <LOQ - 3.80E-01 3.20E-04 <LOQ - <LOQ - <LOQ - <LOQ - 1.17E-03 negligible 
atropine <LOQ - 4.10E-01 1.54E-04 <LOQ - 2.20E+00 8.28E-04 <LOQ - <LOQ - <LOQ - 8.28E-04 negligible 
testosterone <LOQ - <LOQ - <LOQ - 1.09E+00 
7.62E-04 
<LOQ - <LOQ - <LOQ - 
7.62E-04 negligible 
1.09E-03 1.09E-03 negligible 
verapamil 5.30E-01 1.47E-05 2.71E+01 7.54E-04 <LOQ - 1.43E+00 3.96E-05 <LOQ - <LOQ - <LOQ - 7.54E-04 negligible 
losartan <LOQ - <LOQ - <LOQ - 8.45E-01 4.45E-04 <LOQ - <LOQ - 2.18E-01 1.14E-04 4.45E-04 negligible 
zolpidem <LOQ - <LOQ - <LOQ - 2.20E-01 4.24E-04 <LOQ - <LOQ - <LOQ - 4.24E-04 negligible 
clozapine 5.40E-01 
3.68E-04 
5.50E-01 
3.75E-04 
<LOQ - <LOQ - <LOQ - <LOQ - 5.54E-01 
3.77E-04 3.77E-04 negligible 
1.89E-03 1.93E-03 1.94E-03 1.94E-03 negligible 
diazepam <LOQ - <LOQ - <LOQ - 2.50E-01 
1.76E-04 
<LOQ - <LOQ - <LOQ - 
1.76E-04 negligible 
9.62E-05 9.62E-05 negligible 
olanzapine <LOQ - <LOQ - 1.18E+01 8.36E-05 <LOQ - <LOQ - <LOQ - <LOQ - 8.36E-05 negligible 
metoprolol <LOQ - 5.08E+00 8.26E-05 <LOQ - 1.17E+00 1.90E-05 2.64E-01 4.28E-06 <LOQ - 1.25E+00 2.04E-05 8.26E-05 negligible 
barbital <LOQ - <LOQ - <LOQ - <LOQ - 9.48E+01 8.16E-05 <LOQ - <LOQ - 8.16E-05 negligible 
cocaine <LOQ - 1.60E-01 7.01E-05 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 7.01E-05 negligible 
mirtazapine 5.10E-01 1.59E-05 5.30E-01 1.66E-05 1.90E-01 5.94E-06 <LOQ - <LOQ - 2.34E-01 7.31E-06 7.65E-01 2.39E-05 2.39E-05 negligible 
perindopril 1.24E+00 1.25E-06 1.77E+01 1.79E-05 3.79E+00 3.83E-06 2.11E+00 2.13E-06 <LOQ - <LOQ - 6.15E+00 6.21E-06 1.79E-05 negligible 
methadone <LOQ - <LOQ - <LOQ - 6.40E-01 1.68E-05 <LOQ - <LOQ - <LOQ - 1.68E-05 negligible 
quetiapine 1.20E-01 1.20E-05 1.10E-01 1.10E-05 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 1.20E-05 negligible 
lamotrigine 8.57E+00 5.71E-08 1.62E+02 1.08E-06 2.21E+01 1.47E-07 3.34E+01 2.23E-07 <LOQ - <LOQ - 5.54E+01 3.69E-07 1.08E-06 negligible 
benzoylecgonine <LOQ - 2.33E+00 3.42E-07 <LOQ - <LOQ - <LOQ - <LOQ - <LOQ - 3.42E-07 negligible 
 
 
Supplementary Table 2 - MEC data (in ng/L), calculated maxRQ, and MAX RQ values of 42 PhACs, as well as risk levels of study area, in the periods 
investigated (LOQ = limit of quantitation)
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Supplementary Fig. 2 - SSD curves of caffeine (A) and estradiol (B) derived from CAFE 
database with search conditions. HC5 – represents hazard concentration in case of 5% of the 
species in the SSD exhibit an effect 
 
